These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

146 related articles for article (PubMed ID: 38054392)

  • 21. Sodium Glucose Transporter, Type 2 (SGLT2) Inhibitors (SGLT2i) and Glucagon-Like Peptide 1-Receptor Agonists: Newer Therapies in Whole-Body Glucose Stabilization.
    Shepard BD; Ecelbarger CM
    Semin Nephrol; 2021 Jul; 41(4):331-348. PubMed ID: 34715963
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Efficacy and tolerability of sodium-glucose co-transporter-2 inhibitors and glucagon-like peptide-1 receptor agonists: A systematic review and network meta-analysis.
    Hussein H; Zaccardi F; Khunti K; Davies MJ; Patsko E; Dhalwani NN; Kloecker DE; Ioannidou E; Gray LJ
    Diabetes Obes Metab; 2020 Jul; 22(7):1035-1046. PubMed ID: 32077218
    [TBL] [Abstract][Full Text] [Related]  

  • 23. How to position sodium-glucose co-transporter 2 inhibitors in the management of diabetes in acromegaly patients.
    Zaina A; Prencipe N; Golden E; Berton AM; Arad E; Abid A; Shehadeh J; Kassem S; Ghigo E
    Endocrine; 2023 Jun; 80(3):491-499. PubMed ID: 37000406
    [No Abstract]   [Full Text] [Related]  

  • 24. The Role of SGLT2 Inhibitor on the Treatment of Diabetic Retinopathy.
    Sha W; Wen S; Chen L; Xu B; Lei T; Zhou L
    J Diabetes Res; 2020; 2020():8867875. PubMed ID: 33274239
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Glucagon-like peptide-1 receptor agonists and sodium-glucose co-transporter-2 inhibitors as combination therapy for type 2 diabetes: A systematic review and meta-analysis.
    Mantsiou C; Karagiannis T; Kakotrichi P; Malandris K; Avgerinos I; Liakos A; Tsapas A; Bekiari E
    Diabetes Obes Metab; 2020 Oct; 22(10):1857-1868. PubMed ID: 32476254
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Perioperative use of glucagon-like peptide-1 receptor agonists and sodium-glucose cotransporter 2 inhibitors for diabetes mellitus.
    Dhatariya K; Levy N; Russon K; Patel A; Frank C; Mustafa O; Newland-Jones P; Rayman G; Tinsley S; Dhesi J
    Br J Anaesth; 2024 Apr; 132(4):639-643. PubMed ID: 38290906
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Sodium-glucose co-transporter-2 inhibitors and protection from cardiovascular death: Is it all about heart failure?
    Caruso I; Cignarelli A; Laviola L; Giorgino F
    Diabetes Obes Metab; 2021 Sep; 23(9):2194-2196. PubMed ID: 34033214
    [No Abstract]   [Full Text] [Related]  

  • 28. Association between Glucose-lowering Treatments and Risk of Diabetic Retinopathy in People with Type 2 Diabetes: A Nationwide Cohort Study.
    Hasselstrøm Jensen J; Vestergaard P; Hasselstrøm Jensen M
    Curr Drug Saf; 2024; 19(2):236-243. PubMed ID: 37078347
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Comparison of the Effects of Glucagon-Like Peptide Receptor Agonists and Sodium-Glucose Cotransporter 2 Inhibitors for Prevention of Major Adverse Cardiovascular and Renal Outcomes in Type 2 Diabetes Mellitus.
    Zelniker TA; Wiviott SD; Raz I; Im K; Goodrich EL; Furtado RHM; Bonaca MP; Mosenzon O; Kato ET; Cahn A; Bhatt DL; Leiter LA; McGuire DK; Wilding JPH; Sabatine MS
    Circulation; 2019 Apr; 139(17):2022-2031. PubMed ID: 30786725
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Effect of sodium-glucose co-transporter-2 inhibitors on right ventricular function in patients with type 2 diabetes mellitus: A pilot study.
    Patoulias D; Toumpourleka M; Katsimardou A; Zografou I; Stavropoulos K; Imprialos K; Karagiannis A; Doumas M; Papadopoulos C
    Kardiol Pol; 2022; 80(6):696-698. PubMed ID: 35445742
    [No Abstract]   [Full Text] [Related]  

  • 31. Trends in use of sodium-glucose co-transporter 2 inhibitors (SGLT2i) and glucagon-like peptide-1 receptor agonists (GLP-1RA) in Australia in the era of increased evidence of their cardiovascular benefits (2014-2022).
    Lin J; Pearson SA; Greenfield JR; Park KH; Havard A; Brieger D; Day RO; Falster MO; de Oliveira Costa J
    Eur J Clin Pharmacol; 2023 Sep; 79(9):1239-1248. PubMed ID: 37449993
    [TBL] [Abstract][Full Text] [Related]  

  • 32. The effect of sodium-glucose cotransporter 2 inhibitors and glucagon-like peptide 1 agonists on cardiovascular disease in patients with type 2 diabetes.
    Dey AK; Groenendyk J; Mehta NN; Gourgari E
    Clin Cardiol; 2019 Mar; 42(3):406-412. PubMed ID: 30635924
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Predictors of efficacy of Sodium-GLucose Transporter-2 inhibitors and Glucagon-Like Peptide 1 receptor agonists: A retrospective cohort study.
    Scoccimarro D; Cipani G; Dicembrini I; Mannucci E
    Diabetes Metab Res Rev; 2024 Feb; 40(2):e3727. PubMed ID: 37776322
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Use of sodium-glucose co-transporter 2 inhibitors and glucagon-like peptide-1 receptor agonists according to the 2019 ESC guidelines and the 2019 ADA/EASD consensus report in a national population of patients with type 2 diabetes.
    Lim CE; Pasternak B; Eliasson B; Danaei G; Ueda P
    Eur J Prev Cardiol; 2023 Jun; 30(8):634-643. PubMed ID: 36582120
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Incidence and Predictors of Primary Nonadherence to Sodium Glucose Co-transporter 2 Inhibitors and Glucagon-Like Peptide 1 Agonists in a Large Integrated Healthcare System.
    Luo J; Feldman R; Rothenberger S; Korytkowski M; Fischer MA; Gellad WF
    J Gen Intern Med; 2022 Nov; 37(14):3562-3569. PubMed ID: 35048301
    [TBL] [Abstract][Full Text] [Related]  

  • 36. First-Line Therapy for Type 2 Diabetes With Sodium-Glucose Cotransporter-2 Inhibitors and Glucagon-Like Peptide-1 Receptor Agonists : A Cost-Effectiveness Study.
    Choi JG; Winn AN; Skandari MR; Franco MI; Staab EM; Alexander J; Wan W; Zhu M; Huang ES; Philipson L; Laiteerapong N
    Ann Intern Med; 2022 Oct; 175(10):1392-1400. PubMed ID: 36191315
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Choosing GLP-1 receptor agonists or SGLT-2 inhibitors by cardiorenal risk.
    Bailey CJ
    Lancet Diabetes Endocrinol; 2020 Feb; 8(2):97-99. PubMed ID: 31843565
    [No Abstract]   [Full Text] [Related]  

  • 38. Sodium-glucose co-transporter 2 inhibitors and heart failure-the present and the future.
    Nana M; Morgan H; Bondugulapati LNR
    Heart Fail Rev; 2021 Jul; 26(4):953-960. PubMed ID: 32020487
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Dipeptidyl peptidase-4 inhibitors, glucagon-like peptide 1 receptor agonists and sodium-glucose co-transporter-2 inhibitors for people with cardiovascular disease: a network meta-analysis.
    Kanie T; Mizuno A; Takaoka Y; Suzuki T; Yoneoka D; Nishikawa Y; Tam WWS; Morze J; Rynkiewicz A; Xin Y; Wu O; Providencia R; Kwong JS
    Cochrane Database Syst Rev; 2021 Oct; 10(10):CD013650. PubMed ID: 34693515
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Diabetic nephropathy: Renoprotective effects of GLP1R agonists and SGLT2 inhibitors.
    Hocher B; Tsuprykov O
    Nat Rev Nephrol; 2017 Dec; 13(12):728-730. PubMed ID: 28989173
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.